First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the combination regimen of Venclexta® (venetoclax) ...

Scientists have long known that people living at high altitudes, where oxygen levels are low, have lower rates of diabetes ...

Multiple myeloma is a cancer that occurs when a type of white blood cell grows out of control, causing low blood counts, bone and calcium problems, frequent infections and kidney damage. According to ...

The U.S. Food and Drug Administration (FDA) has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), to ...

MAJESTY is the fourth positive Phase III study of Gazyva in immune-mediated diseases, following REGENCY in lupus nephritis, ALLEGORY in systemic lupus erythematosus and INShore in idiopathic nephrotic ...

Long-term zinc use may cause copper deficiency, nerve damage, and immune changes. Learn safe daily amounts and when zinc may cause harm.

Bone marrow transplantation (BMT) is being increasingly and successfully used for several indications including cancer. Cancers that cannot be cured by routine therapies may be salvaged by using BMT.

HARP Doctoral Research Fellow and Haematology Registrar, Queen Mary University of London Stephen Hibbs receives funding from the Wellcome Trust through a HARP doctoral research fellowship. Kari ...

DEAR DR. ROACH: My husband was diagnosed with chronic lymphocytic leukemia (CLL) in 2010 and remained in stage 2 with no effects until 2022. In the interim, he was also diagnosed with atrial ...

Dr. Dima El-Sharkawi discusses how hairy cell leukemia typically presents in patients and the challenges clinicians face in identifying the disease early. At the Hairy Cell Leukemia Foundation 2025 ...

President Donald Trump’s job approval rating among white voters has fallen to the lowest point of his second term, according to a new poll. The Economist/YouGov survey found 47 percent said they ...